NCT04842526 - Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Refractory or Recurrent Neuroblastoma in Children

Interventions

DRUG

Anlotinib and irinotecan combined with temozolomide

Anlotinib, 7mg/m2, PO, was given for 14 days and stopped for 7 days; Irinotecan, 50mg/m2, D1-5, IV; Temozolomide, 100mg/m2, d1-5, PO; Three weeks is a cycle.